Company CVAbout Aurobindo Pharma Ltd. 
Aurobindo Pharma Ltd.
Mid Cap
Pharmaceuticals & Biotechnology
Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
Company Coordinates
Company Details
Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet Hyderabad Telangana : 500038
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 58.59 Cr
Number of Shares
58.59 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
07-Aug-2019
58.59
58.59
23000
1
Issued under ESOP Scheme
07-Aug-2019
58.59
58.59
23000
1
ESOP
27-Mar-2019
58.59
58.59
8000
1
ESOP
30-Mar-2017
58.59
58.59
15000
1
ESOP
30-Mar-2017
58.59
58.59
15000
1
ESOP
09-Mar-2017
58.59
58.59
697823
1
ESOP
09-Mar-2017
58.59
58.59
697823
1
ESOP
09-Mar-2016
58.52
58.52
350036
1
ESOP
09-Mar-2016
58.52
58.52
350036
1
ESOP
19-Jan-2016
58.48
58.48
855000
1
ESOP
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
17.498
Mutual Funds
Held by 38 Schemes (19.3%)
FIIs
Held by 616 FIIs (14.21%)
Promoter with highest holding
Rpr Sons Advisors Private Limited, Mrs.p.suneela Rani (jointly Holding) (33.5%)
Highest Public shareholder
Quant Mutual Fund - Quant Momentum Fund (4.25%)
Individual Investors Holdings
5.25%
Board of Directors
Management
Designation
Remuneration
K Ragunathan
Chairman & Independent Directo
27.0 lacs
Kambam Nityananda Reddy
Executive Director
3.74 cr
M Sivakumaran
Executive Director
2.33 cr
M Madan Mohan Reddy
Executive Director
5.24 cr
P V Ramprasad Reddy
Non Executive Director
5.0 lacs
Avnit Bimal Singh
Independent Non Exe. Director
17.0 lacs
Savita Mahajan
Independent Non Exe. Director
23.0 lacs
Girish Paman Vanvari
Independent Non Exe. Director
27.0 lacs
P Sarath Chandra Reddy
Independent Non Exe. Director
81.63 lacs
Santanu Mukherjee
Independent Director
2.0 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals
11,922.60
97.26%
Other Operating Revenue - Export Incentives
303.72
2.48%
Service Income
16.07
0.13%
Pharmaceuticals
Pharmaceuticals
Other Operating Revenue - Export Incentives
Other Operating Revenue - Export Incentives
Service Income
Service Income
Stock DNARevenue and Profits:
Net Sales:
8,286 Cr
(Quarterly Results - Sep 2025)
Net Profit:
848 Cr
Pharmaceuticals & Biotechnology
INR 70,591 Cr (Mid Cap)
21.00
34
0.33%
-0.03
9.77%
2.03
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
